ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Granules India Q1 FY27 results show strong performance with Revenue growing 22% YoY and PAT up 60%, driven by a significant mix shift towards high-margin Complex Generics.
Granules India delivered record Q1 results, pivoting from volume-driven to a higher-margin complex generic and peptide-led platform. Profitability grew 60% YoY despite regulatory headwinds at Gagillapur, highlighting strong execution and diversification into regulated markets.
Granules India delivered a strong Q1FY27 with 22% YoY revenue growth and 60% PAT growth, driven by a portfolio shift toward high-margin Complex Generics.
Granules India reported Q3FY26 revenue of ₹13,879 Mn (up 22% YoY) and PAT of ₹1,502 Mn (up 28% YoY), driven by Finished Dosage growth in North America and Europe.
Granules India reported Q3FY26 revenue of ₹13,879 Mn with a 22% YoY growth. Strategy focuses on shifting from integrated to complex generics, supported by R&D and US portfolio expansion.
Granules India delivered record performance in FY26, crossing INR 5,000 Cr revenue with 65% gross margins. Management focused on complex generics and the successful integration of Senn Chemicals' peptide business.
Granules India delivered a strong Q3FY26 with 22% YoY revenue growth, despite a temporary EBITDA loss in its Acyl-S peptide CDMO business. Operating performance improved on execution and leverage.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Generics and Peptide CDMO.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift towards high-margin Complex Gx and Peptide CDMO segments.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Gx and Peptide CDMO.